MR-ProADM Risk Stratification for Polytrauma Complications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack accurate and early identification of trauma-related complications in polytrauma patients, particularly sepsis and non-infection related issues like rhabdomyolysis, leading to prolonged intensive care and higher mortality rates.
Innovation Solution
Utilizing mid-regional proadrenomedullin (MR-proADM) levels in patient samples to diagnose, prognose, predict, and risk-stratify trauma-related complications by determining specific cut-off values for polytrauma patients, enabling early differentiation between high and low risk of complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If established biomarkers (CRP, PCT, IL-6) and clinical scores (SOFA, qSOFA) are used for complication identification, then routine clinical monitoring is maintained, but early and accurate prediction of trauma-related complications remains insufficient
Solution Approach 1:
The patent introduces proADM as a new measurement parameter to complement existing biomarkers. By measuring proADM levels in addition to conventional markers, the system achieves earlier and more accurate prediction of complications without discarding established monitoring approaches.
2Loss of time
If proADM is used for early identification of complications, then timely therapeutic decisions can be made, but differentiation between infection-related and non-infection related complications remains challenging
Solution Approach 1:
The patent segments complication prediction into distinct categories by combining proADM with other biomarkers. Different biomarker patterns indicate different complication types: proADM alone for non-infection complications, and proADM combined with PCT for infection-related complications, enabling targeted therapeutic decisions.
3Measurement precision
If multiple biomarkers are combined for comprehensive complication assessment, then prediction accuracy improves, but system complexity increases
Solution Approach 1:
The patent implements a tiered approach where proADM serves as the primary screening marker for all complications. Only when proADM indicates elevated risk does the system activate additional biomarker measurements, avoiding unnecessary complexity for low-risk patients while maintaining comprehensive monitoring for high-risk cases.
Data Source
AI summary
The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of proADM or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication.